<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466502</url>
  </required_header>
  <id_info>
    <org_study_id>1129396</org_study_id>
    <nct_id>NCT03466502</nct_id>
  </id_info>
  <brief_title>Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics</brief_title>
  <official_title>Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring Antibiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nevada, Reno</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Renown Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nevada, Reno</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent
      Clostridium difficile infection in hospitalized patients requiring oral or intravenous
      antibiotics for a suspected or confirmed bacterial infection.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 8, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent Clostridium difficile infection</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
    <description>Diarrheal illness, with at least 3 episodes of watery diarrhea over a 24 hour period and a positive toxin analysis or a positive PCR for Cdiff</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of CDI according to C diff inducing properties of the prescribed antibiotics</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
    <description>Low inducers: aminoglycosides, fosfomycin, glycopeptides, daptomycin, nitrofurantoin, linezolid, polymyxins, rifamycins, antifolates and/or sulfonamides, tetracyclines, tigecycline
Moderate inducers: penicillins, 1st generation cephalosporins, macrolides, azithromycin, streptogramins
High inducers: carbapenems, 2nd and greater generation cephalosporins, fluoroquinolones, clindamycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time between recurrent CDI and the last C diff infection</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrence of CDI in immunocompromised patients</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
    <description>HIV, Organ Transplantation, Current Immunosuppressive therapy, Hypogammaglobulinemia or steroids dose more than prednisone 20mg/day for 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of recurrence of CDI in patients with a history of the NAP-1 strain</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of reported adverse events</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>During hospitalization or the 12 weeks after therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>No oral vancomycin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral vancomycin 125 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral vancomycin 125 mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Vancomycin</intervention_name>
    <description>Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence</description>
    <arm_group_label>Oral vancomycin 125 mg twice daily</arm_group_label>
    <arm_group_label>Oral vancomycin 125 mg daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years

          2. Previous CDI diagnosis (diarrhea- passage of ≥3 loose stools in ≤24 hours and positive
             PCR for toxigenic C. difficile)

          3. Current admission with a suspected or a confirmed bacterial infection requiring
             antibiotics

        Exclusion Criteria:

          1. Active chronic diarrheal illness (eg, Crohn's disease, ulcerative colitis, short bowel
             syndrome)

          2. Previous adverse reactions to oral vancomycin

          3. Requiring metronidazole during hospitalization

          4. Known pregnancy

          5. Expected survival &lt;72 hours

          6. Patients receiving antibiotics only for surgical prophylaxis

          7. Patients who received prophylactic oral vancomycin for the current antibiotic course
             prior to enrollment in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Zion, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renown Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renown Regional Medical Center</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nevada, Reno</investigator_affiliation>
    <investigator_full_name>Lauren Zion, PharmD</investigator_full_name>
    <investigator_title>Pharmacist</investigator_title>
  </responsible_party>
  <keyword>vancomycin</keyword>
  <keyword>Clostridium difficile</keyword>
  <keyword>Clostridium difficile infection</keyword>
  <keyword>Recurrent Clostridium difficile infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

